Bone marrow transplantation in sickle cell anemia
作者:
Carolyn Hoppe,
Mark Walters,
期刊:
Current Opinion in Oncology
(OVID Available online 2001)
卷期:
Volume 13,
issue 2
页码: 85-90
ISSN:1040-8746
年代: 2001
出版商: OVID
数据来源: OVID
摘要:
Hematopoietic cell transplantation (HCT) is a treatment with curative potential for sickle cell disease (SCD). The experience of HCT for persons with β-thalassemia major has been successfully extended to SCD. Currently, the event-free survival rate after allogeneic-matched sibling HCT for SCD is 82%. However, short-term and long-term transplant-related complications remain substantial barriers to HCT, particularly in older patients with life-long complications of SCD. Novel conditioning regimens that minimize transplant-associated toxicity have been developed and show promise for wider application of HCT. Alternative stem cell sources may also expand the availability of HCT for selected patients with SCD.
点击下载:
PDF
(69KB)
返 回